Nuvalent, Inc. NUVL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct Expenses Related To Program by Product | ||||||
| Discovery Programs | $2.8M-7.6% | $3.03M-7.9% | $3.29M-3.6% | $3.42M+60.2% | $2.13M-16.1% | |
| Neladalkib | $26.32M+37.8% | $19.09M-36.5% | $30.05M+6.2% | $28.3M+1.0% | $28.01M+21.3% | |
| NVL-330 | $6.83M+18.6% | $5.76M-6.7% | $6.17M+4.1% | $5.93M+49.7% | $3.96M+30.2% | |
| Zidesamtinib | $12.31M+22.8% | $10.02M-39.9% | $16.67M-3.6% | $17.28M+11.1% | $15.55M-16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Nuvalent, Inc. break its business down?
- Nuvalent, Inc. (NUVL) reports direct expenses related to program by product across 4 parts — Discovery Programs, Neladalkib, NVL-330 and Zidesamtinib. Each is extracted from the segment footnotes and tracked over time.
- Where does Nuvalent, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Nuvalent, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.